Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Current Deferred Revenue (2021 - 2025)

Marker Therapeutics (MRKR) has disclosed Current Deferred Revenue for 4 consecutive years, with $974799.0 as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue changed N/A to $974799.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $974799.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $974799.0 for FY2025, N/A changed from the prior year.
  • Current Deferred Revenue for Q4 2025 was $974799.0 at Marker Therapeutics, down from $1.4 million in the prior quarter.
  • The five-year high for Current Deferred Revenue was $1.4 million in Q3 2025, with the low at $107530.0 in Q3 2023.
  • Average Current Deferred Revenue over 4 years is $863581.7, with a median of $1.1 million recorded in 2021.